(CercleFinance.com) – AstraZeneca announces that it has entered into an exclusive licensing agreement with Eccogene for ‘ECC5004’, an experimental daily oral treatment aimed at combating obesity, type 2 diabetes and other cardiovascular conditions. metabolic.
According to the Anglo-Swedish laboratory, preliminary results from the phase I trial showed a differentiating clinical profile for ECC5004, with good tolerability and an encouraging reduction in glucose and body weight at all dose levels tested compared to the placebo.
This important collaboration between Eccogene and AstraZeneca should help accelerate the development of ECC5004.
Under the terms of the agreement, Eccogene will receive a first upfront payment of $185 million. In addition, Eccogene will also receive up to an additional $1.825 billion in future clinical, regulatory and commercial milestones and tiered royalties on net product sales.
Under the terms of the agreement, AstraZeneca obtains exclusive global rights for the development and commercialization of ECC5004 for any indication in all territories except China, where Eccogene will have the right to co-develop and co- market in China alongside AstraZeneca.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
